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The early development of ABO incompatible (ABOi) kidney
transplantation was complicated by poor graft survival [1]. How-
ever, over the years, ABOi kidney transplantation has evolved with
a much more simpliﬁed desensitization regime and improved graft
survival, which is now similar to that seen with ABO compatible
kidney transplantation [1,2]. We report here our local results of the
pioneering ABOi kidney transplantation program in Malaysia,
which was ﬁrst established in Prince Court Medical Centre (PCMC)
in 2011 that utilized a modiﬁed desensitization regime.2. Material and methods
We undertook a prospective observational study of patients
undergoing ABOi living related kidney transplantation at PCMC.
Ten patients entered our ABOi kidney transplantation program
between July 2011 to December 2013. All donors were either sib-
lings, parents or spouses in line with local regulatory require-
ments. ABO titres were determined using Gel-card methods and
target pre-transplant titer was set at r1:16 for the kidney
transplant to proceed. Outcome data were gathered prospectively
and continuously.3. ABOi transplant protocol (Table 1)
The desensitization protocol ulitilized is summarized in Table 1.
Preoperative antibody removal was achieved with therapeutic
plasma exchange (TPE) or double ﬁltration plasmapharesis (DFPP)x.doi.org/10.1016/j.tpr.2016.04.001
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esponding author.
ail addresses: siyen.tan@princecourt.com (S.Y. Tan),
ao@bigpond.net.au (M. Rao), koh9925@live.com (E.T. Koh).scheduled according to the baseline antiblood group isoagglutinin
level aiming for an anti-ABO antibody titer of r1:16 at transplant.
Most patients also had ABO antibodies removed using the Glyco-
sorb column (Glycorex Transplantation AB, Solvegatan, Sweden) in
addition to TPE (or DFPP), with the Glycosorb columns used
mainly just before surgery to minimize loss of coagulation factors
and maximize antibody removal and these sessions are included
as “plasma exchanges” in the results. Post transplant TPE or DFPP
was performed only for the ﬁrst 2 patients. TPE was performed
using a Gambro Prismaﬂex, and 5% human albumin was the
standard replacement ﬂuid, except in proximity to surgery or renal
biopsy when group AB fresh frozen plasma was also used. In-
travenous immunoglobulin (IVIg) at 0.1 g/kg was administered
after each TPE, and a single dose of 0.5 g/kg was additionally ad-
ministered 12–24 h pretransplant in most patients.
Most patients had protocol renal biopsies at 1 month and 12
months post transplant or when clinically indicated. The primary
outcome measure was patient and graft survival. Data were also
collected on serum creatinine, incidence of acute cellular rejection
(ACR) and antibody mediated rejection (AMR), and infective
complications. This study includes patient outcomes up to and
including October 2015.4. Results (Tables 2 and 3)
The average age of recipient was 42.5 years while average age
of donor was 34 years (Table 2). Median ABO titre was 1:256
which fell to r1:16 at the time of transplantation after a median
of 4 TPE/DFPP and/or IA. Median follow up was 36months with
100% patient and graft survival. Median serum creatinine at follow
up was 108umol/L. Two patients (20%) had ACR which responded
to IV methylprednisolone and there were no problems AMR. ABO
titres remained low in both the early and later stages of follow up.
Routine post-transplant DFPP was performed in the ﬁrst 2 casesunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Standard immunosuppression protocol for ABO-incompatible.
IV Rituximab 375mg/m2 Day -28
Mycophenolate sodium 500 mg BD Begins 10–14 days pre-transplant
Tacrolimus (Prograf) 0.1 mg/kg/day Begins 10–14 days pre-transplant
Methylprednisolone 500 mg iv x2 doses perioperatively Yes
Basiliximab 20 mg (day 0 and day 4) unless 0 HLA Yes
Prednisolone 20 mg OM weaning to 5 mg OM by 3 months post-transplant Yes
Plasma exchange and/or IA with Glycosorb columns According to anti-ABO antibody titer Yes
IVIg 0.1 g/kg post-exchange and 0.5 g/kg at 1 day pre-transplant
Table 2
Patient Demographics.
ABOi# 1 2 3 4 5 6 7 8 9 10 Median
Date of
Operation
01/07/
2011
02/07/
2011
21/02/
2012
30/05/
2012
06/08/2012 07/08/2012 27/04/2013 06/07/
2013
24/08/2013 21/12/2013
Blood Group Donor A B AB A A A B A AB A
Blood Group Recipient O O B O O O O O O B
Donor Relationship Wife Wife Wife Sister Mother Daughter Mother Sister Husband Husband
Donor Age (yrs) 27 34 28 25 63 21 79 58 54 34 34
Creatinine Pre-Tx 56 69 51 50 71 62 50 60 88 75 60
Recipient Age (yrs) 32 55 33 35 42 44 47 43 52 33 42.5
Duration of HD Months 0 5 24 60 72 36 2 60 0.2 15 19.5
Weight Pre-Tx 64.9 61 61 45 51 86 59 61.1 60.6 48.6 61
BMI Pre-Tx 22.7 21.87 22.67 17.14 20.96 34.45 24.55 24.06 26.22 19.97 22.7
Table 3
Patient results.
ABOi# 1 2 3 4 5 6 7 8 9 10 Median
Date of
Operation
01/07/
2011
02/07/
2011
21/02/
2012
30/05/
2012
06/08/
2012
07/08/
2012
27/04/
2013
06/07/
2013
24/08/2013 21/12/2013
Post Operation Month 49.0 49.0 41.0 38.0 36.0 36.0 27.0 25.0 23.0 19.0 36.0
Titre Baseline 1:128 1:512 1:32 1:64 1:128 1:64 1:128 1:256 1:256 (A) /
1:125 (B)
Neat 1:128
Pre-Tx 1:4 1:4 1:16 1:8 1:8 1:8 1:16 1:8 1:8 (A) / 1:8 (B) 1:4 1:8
POD 00 1:4 1:4 1:32 1:4 1:2 1:4 1:2 1:8 N/A N/A 1:4
POD 1 month 1:2 1:8 1:4 1:8 1:2 1:2 1:2 1:8 N/A Negative 1:2
POD 6 month 1:4 1:4 1:16 1:4 1:4 1:2 N/A 1:8 1:4 (A) / 1:4 (B) N/A 1:4
Current 1:4 1:4 1:4 1:8 1:4 1:4 1:4 1:8 1:8 (A) / 1:16
(B)
Negative 1:4
IA Pre-Tx 5 7 2 3 2 2 1 1 2 0 2
DFPP Pre-Tx 0 0 0 2 2 2 3 5 3 2 2
IA Post-Tx 0 0 0 0 0 0 0 0 0 0 0
DFPP Post-Tx 4 2 0 0 0 0 0 0 0 0 0
Creatinine 1 Month 136 118 101 75 140 95 104 137 102 80 103
3 Month(s) 117 109 88 75 153 104 134 139 87 84 106.5
6 Month(s) 123 124 107 77 157 96 144 141 92 97 115
12 Month(s) 119 123 85 71 131 96 166 158 96 86 107.5
24 Month(s) 115 132 106 71 147 98 117 131 (n/a) (n/a) 116
Current 118 116 99 67 147 97 117 136 79 83 107.5
Renal Biopsy Total (#) 6 6 1 1 5 1 4 1 2 1 1.5
Rejection Total (#) 3 0 0 0 2 0 0 0 0 0 0
Type of Rejection Cellular 3 0 0 0 2 0 0 0 0 0 0
ABMR 0 0 0 0 0 0 0 0 0 0 0
C4d 2 1 1 0 1 0 1 0 0 0 0.5
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transplant DFPP and their ABO titres remained low. Infection
complication rate was low at 20% and both cases resolved com-
pletely with antibiotics (Table 3).5. Conclusions
Our observational study suggest that ABOi kidney transplan-
tation may be successfully established in a small but experienced
center performing only 10–20 transplants per year. The critical
component of ABOi transplantation is achieving a sufﬁcient re-
duction in anti-ABO titer to protect the graft from AMR post-
transplant and this may be readily achieved using IV Rituximab,
plasma exchange and/or immunoabsorption together with IVIg
[3]. The risk of coagulopathy associated with TPE (or DFPP) may be
minimized by using immunoabsorption with Glycosorb column for
antibody removal in the hours immediately before the transplant
procedure. Our patients' anti-ABO titers remained low in the
months after transplantation although they were not subjected to
post-transplant TPE.
Our success suggest that ABOi transplantation can be success-
fully developed in a private medical institution with zero technical,
funding or administrative support from government, NGO or
commercial organizations. This may facilitate expansion of ABOi
transplantation to more transplant centers and help increase or-
gan transplantation utilizing ABOi donors. In addition, ABOi
transplantation is a much more viable alternative for patients with
ABOi donors treated in a center with a small transplant program
where the patient pool for a donor exchange program is small [1].Finally, the results of our pioneer ABOi renal transplant pro-
gram with graft and patient survival of 100% at 3 years is ex-
tremely encouraging. Our low complication rates of rejection and
infection suggest that the desensitization and maintenance im-
munosuppression protocol we utilized provided the optimal bal-
ance between maximizing immunosuppression and minimizing
risk of infection. The use of ABO incompatible donors may effec-
tively increase organ donor pools especially in Malaysia where
both cadaver and living related kidney transplant rates remain
poor with sub-optimal outcome. Our results also suggest that the
national ABOi renal transplant program may be effectively in-
troduced and led by a private medical center to complement and
support more established renal transplant programs in govern-
ment institutions which are now beginning to emulate our pro-
tocols and perform their own ABOi renal transplants in light of our
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